<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZIPRASIDONE HYDROCHLORIDE</span><br/>(zip-ra-si'done)<br/><span class="topboxtradename">Geodon<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antipsychotic</span>; <span class="classification">atypical</span><br/><b>Prototype: </b>Clozapine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg, 40 mg, 60 mg, 80 mg capsules; 20 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Unrelated to phenothiazine or butrophenone antipsychotic agents. Exhibits high <i>in vitro</i> binding affinity for the following receptors: dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5HT<sub>2A</sub>, 5HT<sub>2C</sub>, 5HT<sub>1A</sub>, 5HT<sub>1D</sub>, and the alpha-1-adrenergic receptors, and moderate affinity for the histamine H<sub>1</sub> receptor. Antagonist at the D<sub>2</sub>, 5HT<sub>2A</sub> and 5HT<sub>1D</sub> receptors, and an agonist at the 5HT<sub>1A</sub> receptor. Additionally, inhibits synaptic reuptake of serotonin and norepinephrine. Antagonism at other receptors may explain
         some of the other therapeutic and adverse effects (e.g., orthostatic hypotension).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Mechanism of action is unknown; probably related to inhibition of synaptic reuptake of serotonin and norepinephrine through
         antagonism of dopamine type 2 (D<sub>2</sub>) and serotonin type 2 (5HT<sub>2</sub>) antagonism.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of schizophrenia, acute bipolar mania.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Tourette's syndrome.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ziprasidone; history of QT prolongation including congenital long QT syndrome or with other drugs known
         to prolong the QT interval; AV block, bundle branch block, cardiac arrhythmias, congenital heart disease, recent MI or uncompensated
         heart failure; bradycardia, hypokalemia or hypomagnesemia; intravenous administration; neuroleptic malignant syndrome and
         tardive dyskinesia; dehydration or hypovolemia; UV exposure and tanning beds; pregnancy (category C), lactation. Safety and
         efficacy in children are not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of seizures, CVA, dementia, Parkinson's disease, or Alzheimer disease; known cardiovascular disease, conduction abnormalities,
         treatment with antihypertensive drugs; cerebrovascular disease; hepatic impairment; seizure disorder, seizures; breast cancer;
         risk factors for elevated core body temperature; esophageal motility disorders and risk of aspiration pneumonia; suicide potential;
         children &gt;7 y for use in Tourette's syndrome only.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Schizophrenia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 20 mg b.i.d. with food, may increase q2d up to 80 mg b.i.d. if needed <span class="rdroute">IM</span> 10 mg q2h or 20 mg q4h up to max of 40 mg/d<br/><br/><span class="indicationtitle">Acute Mania</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 40 mg b.i.d. with food; may increase q2d up to 80 mg b.i.d. if needed<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: 
         				<small>CONTRAINDICATIONS</small> for this drug. Do <small>NOT</small> administer to anyone with a history of cardiac arrhythmias or other cardiac disease, hypokalemia, hypomagnesemia, prolonged
         QT/QTc interval, or to anyone on other drugs known to prolong the QTc interval. Withhold drug and consult physician if any
         of the foregoing conditions are present.
         		
      </p><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food.</li>
<li>Make dosage adjustments at intervals of <img src="../images/special/greaterorequal.gif"/>2 d.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give deep IM into a large muscle.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Asthenia, myalgia, weight gain, flu-like syndrome, face edema, chills, hypothermia. <span class="typehead">CNS:</span>
<span class="speceff-common">Somnolence,</span> akathisia, dizziness, extrapyramidal effects, dystonia, hypertonia, agitation, tremor, dyskinesias, hostility, paresthesia,
      confusion, vertigo, hypokinesia, hyperkinesias, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity,
      delirium, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination,
      neuropathy. <span class="typehead">CV:</span> Tachycardia, postural hypotension, prolonged QTc interval, hypertension. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> constipation, dyspepsia, diarrhea, dry mouth, anorexia, abdominal pain, vomiting. <span class="typehead">Metabolic:</span> Hyperglycemia, diabetes mellitus. <span class="typehead">Respiratory:</span> Rhinitis, increased cough, dyspnea. <span class="typehead">Skin:</span> Rash, fungal dermatitis, photosensitivity. <span class="typehead">Special Senses:</span> Abnormal vision. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Carbamazepine</b> may decrease <b>ziprasidone</b> levels; <b>ketoconazole</b> may increase <b>ziprasidone</b> levels; may enhance hypotensive effects of <span class="classification">antihypertensive agents</span>; may antagonize effects of <b>levodopa;</b> increased risk of arrhythmias and heart block due to prolonged QTc interval with <span class="classification">antiarrhythmic agents</span>, <b>amoxapine,</b>
<b>arsenic trioxide,</b>
<b>chlorpromazine,</b>
<b>clarithromycin,</b>
<b>daunorubicin,</b>
<b>diltiazem,</b>
<b>dolasetron,</b>
<b>doxorubicin,</b>
<b>droperidol,</b>
<b>erythromycin,</b>
<b>halofantrine,</b>
<b>indapamide,</b>
<b>levomethadyl,</b>
<span class="classification">local anesthetics</span>, <b>maprotiline,</b>
<b>mefloquine,</b>
<b>mesoridazine,</b>
<b>octreotide,</b>
<b>pentamidine,</b>
<b>pimozide,</b>
<b>probucol,</b>
<b>gatifloxacin,</b>
<b>grepafloxacin,</b>
<b>levofloxacin,</b>
<b>moxifloxacin,</b>
<b>sparfloxacin,</b>
<span class="classification">tricyclic antidepressants</span>, <b>tacrolimus,</b>
<b>thioridazine,</b>
<b>troleandomycin;</b> additive CNS depression with <span class="classification">sedative-hypnotics</span>, <span class="classification">anxiolytics</span>, <b>ethanol,</b>
<span class="classification">opiate agonists</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed with 60% reaching systemic circulation. <span class="typehead">Peak:</span> 68 h. <span class="typehead">Metabolism:</span> Extensively metabolized in the liver. <span class="typehead">Elimination:</span> 20% of metabolites excreted in urine, 66% of metabolites excreted in bile. <span class="typehead">Half-Life:</span> 7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline and periodic ECG, serum potassium and serum magnesium, especially with concomitant diuretic therapy. Periodically
            monitor blood glucose.
         </li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Monitor for S&amp;S of torsade de pointes (e.g., dizziness, palpitations, syncope), tardive dyskinesia (see Appendix F) especially
            in older adult women and with prolonged therapy, and the appearance of an unexplained rash. Withhold drug and report to physician
            immediately if any of these develop.
         </li>
<li>Monitor I&amp;O ratio and pattern: Notify physician if diarrhea, vomiting or any other conditions develops which may cause electrolyte
            imbalance.
         </li>
<li>Monitor BP lying, sitting, and standing. Report orthostatic hypotension to physician.</li>
<li>Monitor cognitive status and take appropriate precautions.</li>
<li>Monitor for loss of seizure control, especially with a history of seizures or dementia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Carefully monitor blood glucose levels if diabetic.</li>
<li>Be aware that therapeutic effect may not be evident for several weeks.</li>
<li>Report any of the following to a health care provider immediately: Palpitations, faintness or loss of consciousness, rash,
            abnormal muscle movements, vomiting or diarrhea.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Make position changes slowly and in stages to prevent dizziness upon arising.</li>
<li>Avoid strenuous exercise, exposure to extreme heat, or other activities that may cause dehydration.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>